Back to top

IMMX Maintains Buy Rating by HC Wainwright & Co. -- Price Target Raised to $25

IMMX Maintains Buy Rating by HC Wainwright & Co. -- Price Target Raised to $25

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Immix Biopharma, Inc. (IMMX)